In elderly IBD patients, the proportion of senescent B cells (CD21−CD11c+) increases, while memory B cells (CD27+IgD−) decrease, potentially leading to abnormal anti-infliximab antibody production and affecting drug efficacy (Meng et al., 2023; Childs et al., 2023). Here, CD27 is linked to inflammatory bowel disease.